gorodenkoff/iStock by way of Getty Photographs
Biophytis SA (OTCPK:BPTSY) Tuesday unveiled its strategic outlook for the 12 months and mentioned that 2025 can be decisive for the corporate, with a number of main initiatives to speed up the medical growth of BIO101 (20-Hydroxyecdysone) and its commercialization.
Biophytis will actively pursue
